Clinical trial
A Randomized Double-Blind Phase II Trial of Celecoxib, A COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or 3)
NCT00081263 is registered in ClinicalTrials.gov with Gynecologic Oncology Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Double-Blind Phase II Trial of Celecoxib, A COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or 3)
- Lead sponsor
- Gynecologic Oncology Group
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 30, 2005
- Completion date
- Not reported
- Enrollment
- 130 (actual)
- Sites
- 43
Conditions
As the registry lists them; a condition with its own page is linked.
cervical carcinoma, cervical intraepithelial neoplasia grade 2/3, stage 0 cervical cancer